المؤلفون: Desai KB; Section of Hematology/Oncology, University of Chicago, Chicago, Illinois., Serritella AV; Section of Hematology/Oncology, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois., Stadler WM; Section of Hematology/Oncology, University of Chicago, Chicago, Illinois., O'Donnell PH; Section of Hematology/Oncology, University of Chicago, Chicago, Illinois., Sweis RF; Section of Hematology/Oncology, University of Chicago, Chicago, Illinois., Szmulewitz RZ; Section of Hematology/Oncology, University of Chicago, Chicago, Illinois.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Jun 03; Vol. 30 (11), pp. 2384-2392.

نوع المنشور: Journal Article; Clinical Trial, Phase I

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Phenylthiohydantoin*/administration & dosage , Phenylthiohydantoin*/adverse effects , Phenylthiohydantoin*/therapeutic use , Phenylthiohydantoin*/pharmacokinetics , Benzamides*/administration & dosage , Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology , Nitriles*/administration & dosage , Receptors, Glucocorticoid* , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Male ; Aged ; Middle Aged ; Aged, 80 and over ; Neoplasm Metastasis ; Androgen Receptor Antagonists/therapeutic use ; Androgen Receptor Antagonists/administration & dosage ; Androgen Receptor Antagonists/pharmacokinetics ; Androgen Receptor Antagonists/adverse effects ; Receptors, Androgen/metabolism ; Treatment Outcome

المؤلفون: Agarwal N; Huntsman Cancer Institute, University of Utah (NCI-CCC), Salt Lake City, Utah., Castellano D; Hospital Universitario 12 de Octubre, Madrid, Spain., Alonso-Gordoa T; Hospital Universitario de Ramon y Cajal, Madrid, Spain., Arranz Arija JA; Hospital General Universitario Gregorio Maranon-Oncology, Madrid, Spain., Colomba E; Gustave Roussy Cancerology Institute, Villejuif, France., Gravis G; Institut Paoli-Calmettes, Marseille, France., Mourey L; IUCT-Oncopole Claudius Regaud, Toulouse, France., Oudard S; Georges Pompidou Hospital, University Paris Cité, Paris, France., Fléchon A; Cancérologie Médicale, Centre Léon-Bérard, Lyon, France., González M; Vall d'Hebron Institute of Oncology, Barcelona, Spain., Rey PM; Hospital de la Santa Creu i Sant Pau-Oncology, Barcelona, Spain., Schweizer MT; University of Washington and Fred Hutchinson Cancer Center, Seattle, Washington., Gallardo E; Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, Sabadell, Spain., Johnston E; Eli Lilly and Company, Indianapolis, Indiana., Balar A; Eli Lilly and Company, Indianapolis, Indiana., Haddad N; Eli Lilly and Company, Indianapolis, Indiana., Appiah AK; Eli Lilly and Company, Indianapolis, Indiana., Nacerddine K; Eli Lilly and Company, Indianapolis, Indiana., Piulats JM; Institut Catala d'Oncologia L'Hospitalet, Barcelona, Spain.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Jun 03; Vol. 30 (11), pp. 2377-2383.

نوع المنشور: Journal Article; Multicenter Study; Clinical Trial, Phase I

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Benzimidazoles*/administration & dosage , Benzimidazoles*/adverse effects , Benzimidazoles*/therapeutic use , Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology , Aminopyridines*/administration & dosage , Aminopyridines*/therapeutic use , Aminopyridines*/adverse effects, Humans ; Male ; Aged ; Middle Aged ; Aged, 80 and over ; Neoplasm Metastasis ; Cyclin-Dependent Kinase 4/antagonists & inhibitors ; Treatment Outcome ; Protein Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/administration & dosage

المؤلفون: Archer S; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Brailey PM; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Song M; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Bartlett PD; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Figueiredo I; Cancer Biomarkers Group, The Institute of Cancer Research, London, United Kingdom., Gurel B; Cancer Biomarkers Group, The Institute of Cancer Research, London, United Kingdom., Guo C; Cancer Biomarkers Group, The Institute of Cancer Research, London, United Kingdom.; Prostate Cancer Targeted Therapies Group, Royal Marsden Hospital, Sutton, United Kingdom., Brucklacher-Waldert V; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Thompson HL; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Akinwale J; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Boyle SE; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Rossant C; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Birkett NR; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Pizzey J; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Maginn M; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Legg J; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Williams R; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Johnston CM; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., Bland-Ward P; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom., de Bono JS; Cancer Biomarkers Group, The Institute of Cancer Research, London, United Kingdom.; Prostate Cancer Targeted Therapies Group, Royal Marsden Hospital, Sutton, United Kingdom., Pierce AJ; Crescendo Biologics Ltd., Babraham Research Campus, Cambridge, United Kingdom.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Apr 15; Vol. 30 (8), pp. 1595-1606.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology, Male ; Humans ; Mice ; Animals ; Immunotherapy/methods ; Tumor Microenvironment

المؤلفون: Vellky JE; Department of Pathology, The University of Illinois at Chicago, Chicago, Illinois.; The University of Illinois Cancer Center, Chicago, Illinois., Kirkpatrick BJ; Department of Pathology, The University of Illinois at Chicago, Chicago, Illinois., Gutgesell LC; Department of Pathology, The University of Illinois at Chicago, Chicago, Illinois., Morales M; Department of Pathology, The University of Illinois at Chicago, Chicago, Illinois., Brown RM; Department of Pathology, The University of Illinois at Chicago, Chicago, Illinois., Wu Y; Department of Pathology, The University of Illinois at Chicago, Chicago, Illinois., Maienschein-Cline M; Research Informatics Core, Research Resources Center, The University of Illinois at Chicago, Chicago, Illinois., Notardonato LD; UI Health Division of Hematology/Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois., Weinfeld MS; UI Health Division of Hematology/Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois., Nguyen RH; UI Health Division of Hematology/Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois., Brister E; Research Tissue Imaging Core, Department of Pathology, The University of Illinois at Chicago, Chicago, Illinois., Sverdlov M; Research Histology Core, Research Resource Center, The University of Illinois at Chicago, Chicago, Illinois., Liu L; The University of Illinois Cancer Center, Chicago, Illinois.; Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, Illinois., Xu Z; The University of Illinois Cancer Center, Chicago, Illinois.; Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, Illinois., Kregel S; Department of Cancer Biology, Loyola University Chicago, Chicago, Illinois., Nonn L; Department of Pathology, The University of Illinois at Chicago, Chicago, Illinois.; The University of Illinois Cancer Center, Chicago, Illinois., Vander Griend DJ; Department of Pathology, The University of Illinois at Chicago, Chicago, Illinois.; The University of Illinois Cancer Center, Chicago, Illinois., Reizine NM; The University of Illinois Cancer Center, Chicago, Illinois.; UI Health Division of Hematology/Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Apr 15; Vol. 30 (8), pp. 1530-1543.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/genetics , Prostatic Neoplasms, Castration-Resistant*/metabolism , Benzamides* , Phenylthiohydantoin*, Male ; Humans ; Androgens/therapeutic use ; Neoplasm Recurrence, Local ; Receptors, Androgen/genetics ; Receptors, Androgen/metabolism ; Nitriles/therapeutic use ; Biomarkers ; Castration ; Drug Resistance, Neoplasm/genetics ; Cell Line, Tumor ; Receptor, ErbB-3/genetics

المؤلفون: Halabi S; Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina.; Department of Medicine, Duke Prostate and Urologic Cancer Center, Duke Cancer Institute, Duke University, Durham, North Carolina., Guo S; Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina., Park JJ; Department of Medicine, Duke Prostate and Urologic Cancer Center, Duke Cancer Institute, Duke University, Durham, North Carolina., Nanus DM; Department of Medicine, Weill Cornell Medicine, New York, New York., George DJ; Department of Medicine, Duke Prostate and Urologic Cancer Center, Duke Cancer Institute, Duke University, Durham, North Carolina., Antonarakis ES; University of Minnesota, Minneapolis, Minnesota., Danila DC; Department of Medicine, Weill Cornell Medicine, New York, New York.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Szmulewitz RZ; University of Chicago Medical Center, Chicago, Illinois., McDonnell DP; Department of Medicine, Duke Prostate and Urologic Cancer Center, Duke Cancer Institute, Duke University, Durham, North Carolina.; Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina., Norris JD; Department of Medicine, Duke Prostate and Urologic Cancer Center, Duke Cancer Institute, Duke University, Durham, North Carolina.; Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina., Lu C; Department of Urology, Johns Hopkins University, Baltimore, Maryland., Luo J; Department of Urology, Johns Hopkins University, Baltimore, Maryland., Armstrong AJ; Department of Medicine, Duke Prostate and Urologic Cancer Center, Duke Cancer Institute, Duke University, Durham, North Carolina.; Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Mar 15; Vol. 30 (6), pp. 1152-1159.

نوع المنشور: Multicenter Study; Journal Article

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Neoplastic Cells, Circulating*/pathology , Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/genetics , Prostatic Neoplasms, Castration-Resistant*/pathology , Androstenes* , Benzamides* , Phenylthiohydantoin*, Male ; Humans ; RNA ; Prospective Studies ; Retrospective Studies ; DNA, Complementary/therapeutic use ; Receptors, Androgen/genetics ; Receptors, Androgen/metabolism ; Nitriles/therapeutic use ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/therapeutic use ; Homeodomain Proteins/genetics

المؤلفون: Dorff T; Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California., Horvath LG; Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, Australia., Autio K; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Bernard-Tessier A; Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France., Rettig MB; Departments of Medicine and Urology, University of California, Los Angeles, California.; Department of Medicine, VA Greater Los Angeles, Los Angeles, California., Machiels JP; Department of Medical Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium., Bilen MA; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia., Lolkema MP; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.; Amgen Inc., Thousand Oaks, California., Adra N; Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana., Rottey S; Department of Medical Oncology. Drug Research Unit, Ghent University, Ghent, Belgium., Greil R; Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-CCCIT and Cancer Cluster Salzburg, Salzburg, Austria., Matsubara N; Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan., Tan DSW; Division of Medical Oncology, National Cancer Centre Singapore, Singapore., Wong A; Department of Haematology-Oncology, National University Cancer Institute, Singapore., Uemura H; Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan., Lemech C; Scientia Clinical Research, University of New South Wales, Randwick, Australia., Meran J; Department of Internal Medicine, Hematology, and Internal Oncology, Hospital Barmherzige Brueder, Vienna, Austria., Yu Y; Global Biostatistical Science, Amgen Inc., Thousand Oaks, California., Minocha M; Clinical Pharmacology M&S, Amgen Inc., Thousand Oaks, California., McComb M; Clinical Pharmacology M&S, Amgen Inc., Thousand Oaks, California., Penny HL; Clinical Immunology, Amgen Inc., Thousand Oaks, California., Gupta V; Clinical Biomarkers, Amgen Inc., Thousand Oaks, California., Hu X; Clinical Biomarkers, Amgen Inc., Thousand Oaks, California., Jurida G; Safety TA & Combination Products, Amgen Inc., Thousand Oaks, California., Kouros-Mehr H; Global Development, Amgen Inc., Thousand Oaks, California., Janát-Amsbury MM; Early Development, Oncology, Amgen Inc., Thousand Oaks, California., Eggert T; Early Development, Oncology, Amgen Inc., Thousand Oaks, California., Tran B; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Apr 15; Vol. 30 (8), pp. 1488-1500.

نوع المنشور: Clinical Trial, Phase I; Journal Article

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/pathology , Antineoplastic Agents*/therapeutic use, Male ; Humans ; Prostate-Specific Antigen ; Half-Life ; Treatment Outcome ; Androgen Receptor Antagonists/therapeutic use ; T-Lymphocytes/metabolism

المؤلفون: Abida W; Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York., Hahn AW; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Shore N; CURC, Myrtle Beach, South Carolina., Agarwal N; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah., Sieber P; Keystone Urology Specialists, Lancaster, Pennsylvania., Smith MR; Massachusetts General Hospital, Boston, Massachusetts., Dorff T; City of Hope, Duarte, California., Monk P; The Ohio State University, Arthur James Cancer Hospital, Columbus, Ohio., Rettig M; VA Greater Los Angeles, Los Angeles, California., Patel R; ORIC Pharmaceuticals, South San Francisco, California., Page A; ORIC Pharmaceuticals, South San Francisco, California., Duff M; ORIC Pharmaceuticals, South San Francisco, California., Xu R; ORIC Pharmaceuticals, South San Francisco, California., Wang J; ORIC Pharmaceuticals, South San Francisco, California., Barkund S; ORIC Pharmaceuticals, South San Francisco, California., Pankov A; ORIC Pharmaceuticals, South San Francisco, California., Wang A; ORIC Pharmaceuticals, South San Francisco, California., Junttila MR; ORIC Pharmaceuticals, South San Francisco, California., Multani PS; ORIC Pharmaceuticals, South San Francisco, California., Daemen A; ORIC Pharmaceuticals, South San Francisco, California., Chow Maneval E; ORIC Pharmaceuticals, South San Francisco, California., Logothetis CJ; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Morris MJ; Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Mar 15; Vol. 30 (6), pp. 1111-1120.

نوع المنشور: Clinical Trial, Phase I; Journal Article

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/pathology, Male ; Humans ; Receptors, Glucocorticoid ; Phenylthiohydantoin ; Benzamides/therapeutic use ; Nitriles/therapeutic use ; Antineoplastic Agents, Hormonal/therapeutic use

المؤلفون: Menssouri N; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France., Poiraudeau L; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France., Helissey C; Hôpital d'Instruction des Armées BÉGIN, Saint Mandé, France., Bigot L; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France., Sabio J; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France., Ibrahim T; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France., Pobel C; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France., Nicotra C; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France., Ngo-Camus M; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France., Lacroix L; Experimental and Translational Pathology Platform (PETRA), Genomic Platform-Molecular Biopathology Unit (BMO) and Biological Resource Center, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy Cancer Campus, Villejuif, France.; Department of Medical Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France., Rouleau E; Experimental and Translational Pathology Platform (PETRA), Genomic Platform-Molecular Biopathology Unit (BMO) and Biological Resource Center, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy Cancer Campus, Villejuif, France.; Department of Medical Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France., Tselikas L; Department of Interventional Radiology, Gustave Roussy Cancer Campus, Villejuif, France., Chauchereau A; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France., Blanc-Durand F; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Bernard-Tessier A; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Patrikidou A; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Naoun N; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Flippot R; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Colomba E; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Fuerea A; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Albiges L; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Lavaud P; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., van de Wiel P; InnoSIGN, High Tech Campus 11, Eindhoven, the Netherlands., den Biezen E; InnoSIGN, High Tech Campus 11, Eindhoven, the Netherlands., Wesseling-Rozendaal Y; InnoSIGN, High Tech Campus 11, Eindhoven, the Netherlands., Ponce S; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France., Michiels S; Oncostat U1018, Inserm, University of Paris-Saclay, Labelled Ligue Contre le Cancer, Villejuif, France., Massard C; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France., Gautheret D; Department of Biostatistics and Epidemiology, Gustave Roussy, University of Paris-Saclay, Villejuif, France.; PRISM Center for Personalized Medicine, Gustave Roussy Cancer Campus, Villejuif, France., Barlesi F; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France., André F; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France.; Department of Biostatistics and Epidemiology, Gustave Roussy, University of Paris-Saclay, Villejuif, France.; PRISM Center for Personalized Medicine, Gustave Roussy Cancer Campus, Villejuif, France., Besse B; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France.; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.; Department of Biostatistics and Epidemiology, Gustave Roussy, University of Paris-Saclay, Villejuif, France., Scoazec JY; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France.; Experimental and Translational Pathology Platform (PETRA), Genomic Platform-Molecular Biopathology Unit (BMO) and Biological Resource Center, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy Cancer Campus, Villejuif, France.; Department of Medical Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France., Friboulet L; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France., Fizazi K; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France.; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France., Loriot Y; Inserm U981, Molecular Predictors and New Targets in Oncology, Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France.; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France.; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.; Department of Biostatistics and Epidemiology, Gustave Roussy, University of Paris-Saclay, Villejuif, France.; PRISM Center for Personalized Medicine, Gustave Roussy Cancer Campus, Villejuif, France.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Nov 01; Vol. 29 (21), pp. 4504-4517.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/genetics , Prostatic Neoplasms, Castration-Resistant*/pathology, Male ; Humans ; Receptors, Androgen/genetics ; Hedgehog Proteins ; Prospective Studies ; Biomarkers, Tumor ; Drug Resistance, Neoplasm/genetics ; Androgen Receptor Antagonists/pharmacology ; Androgen Receptor Antagonists/therapeutic use ; Genomics ; Nitriles

المؤلفون: Geng C; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zhang MC; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Manyam GC; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Vykoukal JV; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fahrmann JF; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas., Peng S; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wu C; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Park S; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kondraganti S; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wang D; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Robinson BD; Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York.; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York., Loda M; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York., Barbieri CE; Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York.; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.; Department of Urology, Weill Cornell Medicine, New York, New York., Yap TA; Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.; The Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas., Corn PG; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hanash S; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas., Broom BM; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Pilié PG; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Thompson TC; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Nov 01; Vol. 29 (21), pp. 4464-4478.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/genetics , Prostatic Neoplasms*/drug therapy , Prostatic Neoplasms*/genetics , Prostatic Neoplasms*/metabolism, Male ; Humans ; Poly(ADP-ribose) Polymerase Inhibitors/pharmacology ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use ; NF-kappa B/genetics ; Transcription Factors/genetics ; Mutation ; Nucleotidyltransferases/genetics ; Nucleotidyltransferases/therapeutic use ; Tumor Microenvironment

المؤلفون: Tolmeijer SH; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Boerrigter E; Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands., Sumiyoshi T; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada., Kwan EM; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada., Ng SWS; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada., Annala M; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland., Donnellan G; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada., Herberts C; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada., Benoist GE; Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands., Hamberg P; Department of Medical Oncology, Franciscus Gasthuis & Vlietland, Rotterdam/Schiedam, the Netherlands., Somford DM; Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, the Netherlands., van Oort IM; Department of Urology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands., Schalken JA; Department of Urology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands., Mehra N; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., van Erp NP; Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands., Wyatt AW; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.; Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British of Columbia, Canada.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Aug 01; Vol. 29 (15), pp. 2835-2844.

نوع المنشور: Research Support, Non-U.S. Gov't; Journal Article

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/genetics , Prostatic Neoplasms, Castration-Resistant*/pathology , Circulating Tumor DNA*/genetics , Circulating Tumor DNA*/blood, Male ; Humans ; Prospective Studies ; Nitriles/therapeutic use ; Androgen Receptor Antagonists/therapeutic use